Mezavant

Mesalazine, the active ingredient in Mezavant, is a 5‑aminosalicylic acid (5‑ASA) presented as an oral formulation for oral use. It is used to treat ulcerative colitis by reducing inflammation in the intestinal lining of adults.

GNH USA supplies Mezavant as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mezavant belongs to the 5‑ASA class and is employed in the management of ulcerative colitis, a chronic inflammatory bowel disease. - Ulcerative colitis (induction of remission): helps achieve clinical remission in active disease. - Ulcerative colitis (maintenance of remission): helps sustain remission and prevent relapse. - Inflammatory bowel disease (IBD) management: reduces mucosal inflammation and promotes healing of the colon.

Adverse reactions may occur with mesalazine therapy and are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Abdominal pain: cramping or discomfort in the abdomen. - Headache: transient mild to moderate headache. - Rash: skin irritation or mild erythema.

Serious or Rare Side Effects: - Myocarditis: inflammation of the heart muscle. - Severe allergic reaction (anaphylaxis): rapid onset of swelling, breathing difficulty. - Pancreatitis: inflammation of the pancreas presenting with abdominal pain.

Before initiating therapy, clinicians should consider several safety measures. - Renal function monitoring: assess serum creatinine and eGFR regularly. - Hepatic function monitoring: check liver enzymes periodically. - Blood dyscrasia surveillance: perform complete blood counts to detect anemia or leukopenia. - Hypersensitivity avoidance: discontinue if signs of allergic reaction appear. - Pregnancy considerations: use only if potential benefit outweighs unknown risks. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Mesalazine may interact with other medicines, requiring attention to the level of risk.

Major Interactions (Avoid): - Azathioprine: increased risk of bone marrow suppression. - Warfarin: potentiation of anticoagulant effect, raising bleeding risk. - Methotrexate: heightened toxicity and hepatic injury.

Moderate Interactions (Monitor Closely): - NSAIDs: additive gastrointestinal irritation. - Oral contraceptives: possible reduction in contraceptive efficacy. - Lithium: potential alteration of serum lithium concentrations.